TY - JOUR
T1 - Doxycycline or Oral Corticosteroids for Nasal Polyps
AU - Grammer, Leslie C.
N1 - Funding Information:
This work is supported by the Ernest S Bazley Trust to Northwestern University and Northwestern Memorial Hospital .
Funding Information:
Conflicts of interest: L. C. Grammer has received research and travel support from the National Institutes of Health, Food Allergy Network, and S&C Electric ; has received the Bazley Foundation Grant; has received consultancy fees from Astellas Pharmaceuticals ; is employed by Northwestern University and the Northwestern Medical Faculty Foundation; has received lecture fees from the AAAAI and Beth Israel Hospital; and receives royalties from Lippincott, UpToDate, BMJ, and Elsevier.
PY - 2013/9
Y1 - 2013/9
N2 - The study by Van Zele etal reports positive results for a randomized, double-blind, placebo-controlled trial that used either 20 days of doxycycline (200 mg the first day, followed by 100 mg daily) or 20 days of a tapering schedule of methyl prednisolone (32 mg on days 1-5, 16 mg on days 6-10, and 8 mg on days 11-20) for the treatment of nasal polyps. The primary end point was reduction in nasal polyp score which was graded 0 to 4 on each side, resulting in a score range of 0 to 8; the score was determined at baseline and weeks 1, 2, 4, 8, and 12. Entry criteria required that the patient either have recurrent polyps after surgery or massive polyps (grade 3 or 4); the total polyp score in each of the 3 groups averaged approximately 6. The patient population in this study was therefore at the severe end of the spectrum; results may not be generalizable to patients with milder disease.
AB - The study by Van Zele etal reports positive results for a randomized, double-blind, placebo-controlled trial that used either 20 days of doxycycline (200 mg the first day, followed by 100 mg daily) or 20 days of a tapering schedule of methyl prednisolone (32 mg on days 1-5, 16 mg on days 6-10, and 8 mg on days 11-20) for the treatment of nasal polyps. The primary end point was reduction in nasal polyp score which was graded 0 to 4 on each side, resulting in a score range of 0 to 8; the score was determined at baseline and weeks 1, 2, 4, 8, and 12. Entry criteria required that the patient either have recurrent polyps after surgery or massive polyps (grade 3 or 4); the total polyp score in each of the 3 groups averaged approximately 6. The patient population in this study was therefore at the severe end of the spectrum; results may not be generalizable to patients with milder disease.
KW - Doxycycline
KW - ECP
KW - Methyl prednisolone
KW - Polyps
UR - http://www.scopus.com/inward/record.url?scp=84883311012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883311012&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2013.04.010
DO - 10.1016/j.jaip.2013.04.010
M3 - Article
C2 - 24565635
AN - SCOPUS:84883311012
SN - 2213-2198
VL - 1
SP - 541
EP - 542
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 5
ER -